GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (GREY:BVNXF) » Definitions » Research & Development

Bioventix (Bioventix) Research & Development : $-0.04 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Bioventix Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Bioventix's Research & Development for the six months ended in Dec. 2023 was $-0.02 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04 Mil.

Bioventix Research & Development Historical Data

The historical data trend for Bioventix's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Research & Development Chart

Bioventix Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.05 -0.03 -0.03

Bioventix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.01 -0.02 -0.02

Bioventix Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventix  (GREY:BVNXF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bioventix Research & Development Related Terms

Thank you for viewing the detailed overview of Bioventix's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioventix (Bioventix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (GREY:BVNXF) » Definitions » Research & Development
Comparable Companies
LSE:FARN LSE:OXB LSE:ARIX LSE:HVO LSE:SCLP LSE:FUM LSE:REDX LSE:OBD LSE:4BB LSE:ETX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BVXP.GB:UK BVXP:UK 51B:Germany
Address
East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX
Website
http://www.bioventix.com
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (Bioventix) Headlines

From GuruFocus

Urbem's 'Wonderful Business' Series: Bioventix

By Steven Chen Steven Chen • 12-13-2019

Bond Proxies: Playing Defense for Alpha

By Steven Chen Steven Chen • 07-05-2019